ODOndřej Daum

Ondřej Daum

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ondřej Daum has a total of 162 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diagnostic utility of targeted next-generation sequencing in indeterminate pancreaticobiliary cytology and small biopsy specimens: a prospective cohort study

    by Kristýna Behenská, OndřEj Daum, Magdaléna Daumová, Luděk Bouchner, Zdeněk Chudáček, JiřIna Pintová, Tomáš Vaněček, Petr Martínek, Roman Mezencev, Mihaela Farcas, et al.

    Pancreaticobiliary cytology is a highly specific but variably and often insufficiently sensitive diagnostic method. This study evaluated the utility of next-generation sequencing (NGS) in difficult-to-classify pancreaticobiliary specimens. A total of 136 patients were prospectively included, with cytology or small biopsy specimens from the pancreas ( n = 74), extrahepatic biliary tree ( n = 56), pancreatic duct ( n = 4), gallbladder ( n = 1), and peripancreatic lymph node ( n = 1). All cases were diagnosed by cytopathologists with expertise in pancreaticobiliary (cyto)pathology using 2022 WHO Reporting System for Pancreaticobiliary Cytopathology. Large scale pan-cancer panel was used for NGS testing. Forty-five cases (33,1%) were non-analyzable by NGS, and no genetic changes were found in 21 cases (23,1% of analyzable cases). Separate acquisition and storage of cytology/biopsy materials in RNAlater solution significantly decreased the rate of non-analyzable samples (23.3% versus 44.4%; Fisher’s exact test: p  = 0.0108, OR = 0.379, 95% CI 0.182–0.792). Diagnostic genetic alterations were identified in 70/91 of analyzable cases (76.9%). Suspicion was raised for the presence of germline mutation in 10 patients. Potentially druggable alterations ( n = 42) were found in 36/91 patients (39,5%), including mutations in homologous recombination genes, PI3K/AKT/mTOR pathway, Cyclin D1-CDK4/6-Rb pathway, and potentially targetable KRAS mutations ( KRAS G12D mutation occurred in 19/41 [46,3%] of KRAS -mutated tumors). Supplementing pancreaticobiliary (cyto)pathology with information from NGS increased the sensitivity for tumor diagnosis from 35.9% to 86.6% (with specificity 100%), improved negative predictive value from 14.2% to 41.2%, and enhanced overall diagnostic accuracy from 42.1% to 87.8%, respectively. In challenging cases, NGS significantly improves preoperative pancreaticobiliary diagnosis and informs clinical decision-making.


  • Open Access

    Spatial Profiling and Prognostic Role of CD169+ Macrophages in Colorectal Cancer From Adjacent Nontumor Mucosa to Liver Metastasis

    by Wenjing Ye, Sergii Pavlov, Esraa Ali, Filip Ambrozkiewicz, Lenka Červenková, OndřEj Vyčítal, Petr Hošek, OndřEj Daum, Václav Liška, Kari Hemminki, et al.

    Background: CD169+ cells represent a distinct subset of macrophages with potential immunomodulatory roles, but their function in colorectal cancer (CRC) progression remains unclear. This study focuses on the spatial profiling and prognostic significance of CD169+ macrophages in adjacent nontumor mucosa (NM), primary CRC (pCRC), and synchronous or metachronous liver metastases (LM). Materials and Methods: We enrolled into this retrospective cohort study patients who underwent resection of both pCRC with adjacent NM and synchronous LM ( N = 55) or metachronous LM ( N = 44). We applied immunohistochemical staining and computer‐assisted image analysis to quantify CD169+ cell density in the NM, pCRC, synchronous, and metachronous LM. Correlations between CD169+ macrophages and T cells were evaluated. Associations between CD169+ cell density and overall survival (OS) of the patients were assessed. Results: CD169+ cell density was greater in NM than in the tumor center (TC) of pCRC and in the peritumor (PT) region of LM compared to pCRC. The synchronous group exhibited a higher density of CD169+ cells than the metachronous group in the inner margin (IM) of pCRC, the TC, and the outer margin (OM) of LM. CD169+ cells were more abundant in the exterior than in the interior tumor areas in both pCRC and LM. Positive correlations were observed between densities of CD169+ macrophages with CD3+ and CD8+ lymphocytes. In the synchronous group, a high density of CD169+ macrophages in the TC of pCRC was associated with longer OS, whereas a high density in the PT of LM was associated with shorter OS. High density of CD169+ macrophages in the OM of metachronous LM was associated with poor survival. Conclusion: Our study highlights context‐dependent prognostic associations of CD169+ macrophages in CRC. While high CD169+ macrophage density in the TC of pCRC was linked to favorable survival in the synchronous group, increased density in both synchronous and metachronous LM was associated with adverse outcomes. Further prospective studies and functional investigations are needed to validate these observations.

  • Open Access

    Non-viral HCC miRNA profiling reveals miR-1972 as a potential positive prognostic marker

    by Venkata Ramana Mallela, Marie Rajtmajerová, Esraa Ali, Lenka Červenková, Andriy Trailin, Petr Hošek, Richard Pálek, OndřEj Daum, Václav Liška, Kari Hemminki, et al.

    Hepatocellular carcinoma (HCC) is the third deadliest cancer worldwide. Its high mortality is primarily attributed to late-stage diagnosis. While mutations in driver genes, such as those encoding β-catenin (CTNNB1), tumor protein p53 (TP53), and telomerase reverse transcriptase promoter (TERTp) are well-documented in the literature, dysregulation of microRNAs (miRNAs), small non-coding RNAs that serve as crucial translational regulators, remains poorly understood. We conducted microRNA profiling by microarrays in 45 paired (tumor and non-tumor adjacent tissue) samples from non-viral HCC patients. We performed clinical correlation, ROC analysis and survival analysis of time to recurrence (TTR), disease-free survival (DFS) and overall survival. We identified 23 significantly dysregulated miRNAs (p ≤ 0.05, fold change ≥2). We investigated their differential expression and its relationship with clinical and pathological variables. Further, we found that miRNA-1972 may serve as an important positive prognostic marker because its high levels were associated with longer TTR and DFS. Significant positive results were obtained in receiver operating characteristic analysis for miR-1972, miR-3651 and miR-486-5p. miRNA-1972 is a strong prognostic marker in non-viral HCC. Dysregulation of several other miRNAs relates to pathological variables such as amount of stroma within tumor, microvascular invasion and micronodularity.

  • Open Access

    MMR deficiency is frequent in colorectal carcinomas with diffuse SLFN11 immunostaining: clinicopathologic and molecular study of 31 cases identified among 3,300 tumors

    by Maciej Kaczorowski, Małgorzata Chłopek, Ondřej Daum, Kris Ylaya, Tomáš Vaněček, Magdalena Szczepaniak, Karol Krawczyk, Artur Kowalik, Michal Michal, Jerzy Lasota, et al.

    Schlafen 11 (SLFN11), a regulator of cell fate following DNA injury, sensitizes tumor cells to DNA‐damaging agents. Patients with SLFN11‐positive tumors may benefit from DNA‐damaging chemotherapies. SLFN11 has been studied in different types of cancer including colorectal carcinomas. However, colorectal carcinomas with diffuse positivity (expression in ≥80% of tumor cells) have not been meticulously characterized. SLFN11 immunostaining of tumor microarrays (TMAs) with 3,300 primary CRCs identified 65 (~2.0%) tumors with focal staining (MLH1 (n = 2), MSH2, MSH6, and PMS2 germline mutations were identified in 25% (5/20) of patients with mismatch repair deficient tumors. BRAF p.V600E mutation was found in 45% (9/20) of mismatch repair deficient, but only 1 of 11 proficient tumors. Colorectal carcinomas with diffuse SLFN11 positivity were often mismatch repair deficient tumors with their typical clinical, morphological, and molecular characteristics.


  • Open Access

    Small nucleolar RNA expression profiles: A potential prognostic biomarker for non-viral Hepatocellular carcinoma

    by Venkata Ramana Mallela, Phanindra Babu Kasi, Dattatrya Shetti, Andriy Trailin, Lenka Cervenkova, Richard Palek, Ondřej Daum, Vaclav Liska, Kari Hemminki, Filip Ambrozkiewicz

    Hepatocellular carcinoma (HCC) is a challenging cancer with high mortality rates, limited predictability, and a lack of effective prognostic indicators. The relationship between small nucleolar RNAs (snoRNAs) and HCC is poorly understood. Based on the literature data, snoRNA studies were primarily focused on viral-related causes of HCC, such as Hepatitis B or C viruses (HBV or HCV). According to these studies, we selected four snoRNAs (snoRA12, snoRA47, snoRA80E, and snoRD126) for exploration in the context of non-viral-related causes, including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver diseases (NAFLD), and alcohol steatohepatitis. The primary goal of this study was to gain a deeper understanding of how snoRNA expression affects patient outcomes and whether it can serve as a prognostic tool for non-viral HCC. We conducted a study on tissue samples from 35 HCC patients who had undergone resection at Pilsen University Hospital. SnoRA12, snoRA47, snoRA80E, and snoRD126 were studied by quantitative real-time PCR (qRT-PCR) in tumor and non-tumor adjacent tissue (NTAT) samples. Kaplan-Meier analysis was performed to assess the association of snoRNAs expression levels with patient outcomes: time to recurrence (TTR), disease-free survival (DFS) and overall survival (OS). In tumor tissues, snoRA12, snoRA47 and snoRA80E were upregulated, while snoRD-126 was downregulated compared to NTAT. Low expression of snoRA47 and snoRD126 in patients was associated with longer TTR and DFS. The individual expression of snoRA12 and snoRA80E did not show associations with TTR and DFS. However, a combination of medium expression of snoRD126 and snoRA80E was associated with longer TTR and DFS, while high and low expressions of the combined snoRA126 and snoRA80E showed no significant association with TTR, DFS, and OS. Conversely, a combination of high expression of snoRA12 and snoRD126 was associated with shorter TTR. In conclusion, the results indicate that snoRA47 and snoRD126 exhibit good prognostic power specifically for non-viral related HCC. Both snoRA47 and snoRD126 showed favorable prognostication in single and combined analysis when assessing patient outcomes. Also, in combination analysis, snoRA80E and snoRA12 showed favorable prognosis, but not alone.


  • Protein expression and localization of ABC transporters in pancreatic adenocarcinoma: Prognostic role of ABCC8

    by Lenka Cervenkova, Richard Palek, Vladimira Moulisova, Vaclav Liska, Ondrej Daum, Beatrice Mohelnikova-Duchonova, Pavel Soucek


  • Exome Sequencing of Paired Colorectal Carcinomas and Synchronous Liver Metastases for Prognosis and Therapy Prediction

    by Viktor Hlaváč, Lenka Červenková, Simona Šůsová, Petr Holý, Václav Liška, Ondřej Vyčítal, Ondřej Šorejs, Ondřej Fiala, Ondřej Daum, Pavel Souček

    PURPOSE: Analysis of somatic variant profiles in retrospectively collected pairs of primary tumors and synchronous liver metastases from surgically treated patients with colorectal carcinomas. Mutational profiles were compared between groups of patients stratified by response to chemotherapy and survival. PATIENTS AND METHODS: The study used whole-exome sequencing of tumor sample pairs from 20 patients diagnosed and treated at a single center. The Cancer Genome Atlas COAD-READ data set (n = 380) was used for validation in silico, where possible. RESULTS: The most frequently altered oncodrivers were APC (55% in primaries and 60% in metastases), TP53 (50/45), TRIP11 (30/5), FAT4 (20/25), and KRAS (15/25). Harboring variants with a high or moderate predicted functional effect in KRAS in primary tumors was significantly associated with poor relapse-free survival in both our sample set and the validation data set. We found a number of additional prognostic associations, including mutational load, alterations in individual genes, oncodriver pathways, and single base substitution (SBS) signatures in primary tissues, which were not confirmed by validation. Altered ATM, DNAH11, and MUC5AC, or a higher share of SBS24 signature in metastases seemed to represent poor prognostic factors, but because of a lack of suitable validation data sets, these results must be treated with extreme caution. No gene or profile was significantly associated with response to chemotherapy. CONCLUSION: Taken together, we report subtle differences in exome mutational profiles between paired primary tumors and synchronous liver metastases and a distinct prognostic relevance of KRAS in primary tumors. Although the general scarcity of primary tumor-synchronous metastasis sample pairs with high-quality clinical data makes robust validation difficult, this study provides potentially valuable data for utilization in precision oncology and could serve as a springboard for larger studies.


  • Open Access

    T- and B-Cells in the Inner Invasive Margin of Hepatocellular Carcinoma after Resection Associate with Favorable Prognosis

    by Andriy Trailin, Lenka Červenková, Filip Ambrozkiewicz, Esraa Ali, Phanindra Kasi, Richard Pálek, Petr Hošek, Vladislav Třeška, Ondrej Daum, Zbyněk Tonar, et al.

    In this retrospective study on 67 patients with hepatocellular carcinoma (HCC), after tumor resection, we evaluated the significance of CD3+ and CD8+ T-lymphocytes and CD20+ B-lymphocytes in tumor and non-tumor liver for time to recurrence (TTR), disease-free survival (DFS) and overall survival. After immunohistochemical staining, the density of nucleated lymphocyte profiles (QA) was estimated stereologically in the tumor center (TC), inner margin (inn M), outer margin (out M), peritumor and non-tumor liver. In TC, intermediate and high QA of CD8+ cells predicted longer TTR, whereas CD3+ and CD20+ were predictive only at high QA. DFS was predicted by high QA of CD3+, CD8+ and CD20+ cells in TC. The inn M harbored smaller QA of CD3+, CD8+ and CD20+ lymphocytes than out M. In contrast to out M, high T-cells’ QA and intermediate and high B-cell QA in inn M predicted longer TTR and DFS. High inn M/out M QA ratios of CD3+ and CD20+ cells were associated with longer TTR and DFS, whereas high inn M/out M QA ratio of CD8+ was predictive only for DFS. Patients with intermediate-high QA of combined CD8+ and CD20+ cells in inn M showed longer TTR and DFS, compared to CD8+-high or CD20+-high alone. Our findings highlight overall heterogeneity of the tumor invasive margin, the importance of inn M, and the predictive role of B-cells.


  • Morphological features useful in the differential diagnosis between undifferentiated carcinoma and gastrointestinal stromal tumor

    by Bohuslava Vankova, Kristyna Behenska, Meret Bauer, Monika Sedivcova, Magdalena Daumova, Abbas Agaimy, Michal Michal, Ondrej Daum


  • Nonsyndromic Intestinal Lipomas are Probably not Associated With Mutations of PDGFRA

    by Magdalena Dubova, Monika Sedivcova, Bohuslava Saskova, Sarka Hadravska, Ondrej Daum

    The purpose of this study was to test the hypothesis that intestinal lipomas occurring in patients devoid of signs of PDGFRA-mutant syndrome might represent sporadic counterparts of familial lipomatous tumors occurring in the spectrum of tumors associated with PDGFRA mutations. PDGFRA-mutant syndrome may manifest with gastrointestinal stromal tumors, Vanek tumors, fibrous tumors, and lipomatous tumors. Until now there has been no molecular genetic study of PDGFRA mutations in intestinal lipomas published in the world literature. A series of 20 intestinal lipomas were obtained from 17 patients, and mutational analysis of exons 12, 14, and 18 of the PDGFRA gene was performed. None of the 16 analyzable tumors showed mutations in PDGFRA. Thus, PDGFRA mutations probably do not play an important role in the development of sporadic lipomas of the intestines.